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1. Introduction 
 Hodgkin lymphoma (HL) is the malignancy of the lymphatic system, it 
consists of 12-18% of all lymphomas. The most common symptoms are enlarged lymph 
nodes (lymphadenomegaly), liver- and spleen enlargement (hepato-splenomegaly). 
Lymph nodes are often involved in the cervical, supraclavicular and mediastinal region. 
Infradiaphragmatic, especially extranodal involvement is rare. General symptoms („B” 
symptoms) are weight loss exceeding 10%, night sweats, and undulant type – Pel-
Ebstein-like – fever. Laboratory findings are increased erythrocyte sedimentation, 
eosinophilia, lekocytosis, lymphopenia, thrombocytosis, hypalbuminaemia, perhaps 
anemia. 
 Previously, the goal of treatment was to improve survival rate of patients. 
Nowadays, long-term side effects came to the front with improvement of survival; 
therefore avoiding over- or undertreatment is of interest. Our workgroup published data 
about cardiovascular, thyroid-, parathyroid, renal and ureter impairment, carotis 
stenosis, secondary malignancies, postirradiation cardiotoxicity, parodontological 
complications and quality of life of HL survivors. Our current work examined the 
pathobiology of HL, investigated clinical experiences gained in our Department with 
patients treated between 1983 and 2011 and long-term pulmonary side effects of HL 
treatment. 
 
2. Literature background 
2.1 Diagnosis 
 The diagnosis of HL is based on histology, which the biopsy of the involved 
lymph node is required for. Core biopsy could be considered, but fine needle aspiration 
is unacceptable due to the small number of the tumor cells compared to the tumor mass 
(1-5%) in contrast with solid tumors. The rest is of the mass in HL is inflammatory-
fibrotic mass. 
 The 2016 World Health Organization (WHO) did not bring too much change 
in the histological classification of HL. It is still divided into nodular lymphocyte 
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predominant (NLPHL) and classical HL (cHL), which further subdivided into the 
known histological subtypes: lymphocyte rich (cLR), nodular sclerosis (cNS), mixed 
cellularity (cMC), lymphocyte depletion (cLD) and not determined (ND). 
 
2.2 Pathogenesis 
 Although the B-cell origin of Hodgkin/ Reed-Sternberg (HRS) cells is now 
obvious, but the explicit reason of HL is still unknown. Genetic, immunologic and 
environmental factors can be blamed causing HL. HRS cells are monoclonal, germinal 
center originated pre-apoptotic B-cells, which carry rearranged, somatically 
hypermutated immunoglobulin heavy chains (IgVH), lost their B-cell phenotype, but 
express membrane markers characteristic for other lympho-hemopoetic cells and 
proteins regulating their abnormal transcription. 
 Several signaling pathways have been reported to prevent or modulate 
apoptosis, eventually causing progression of lymphoma. The most important is the 
constitutive upregulation of NF- κB, JAK-STAT, which is an important mediator of 
cytokine signaling and active phosphatidil 3-kinase (PI3K)-Akt pathway, which inhibits 
apoptosis and activates cell cycle. 
 The pathogenic role of Epstein-Barr virus (EBV) is well known. Patients, who 
already underwent infectious mononucleosis develop EBV+ HL with 3-fold probability 
compared to the general population. EBV+ HRS cells express latent membrane protein 
-1 and -2 (LMP-1, LMP-2). LMP-1 imitated CD40 receptor, leading to NF- κB 
activation and it can also stimulate infiltrating lymphocytes, while LMP-2 provides B-
cell signaling by substituting B-cell receptor. FISH can evince clonal numeric 
aberrations in every cHL subtype. Recently, 9p24.1 chromosome amplification was 
reported to overexpress programmed cell death ligand 1 (PD-L1) in HRS cells – 
especially in cNS subtype. EBV infection further increases expression of PD-1L, 
therefore increased expression can be detected at the case of EBV+ HL patients. PD 
protein helps inhibiting T-cell mediated immunresponse, hence bonding PD-L1 and 
PD-L2 to PD-1 expressed by T-cells leads to apoptosis of cytotoxic T-cells, increasing 
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numbers of immunosupressive Treg cells, thus leading to the inhibition of 
immuneresponse, which eventually results in immunescape and survival of the HRS 
cells. Microenvironmental cells help not only the proliferation of HRS cells but creating 
such environment in which effective immuneresponse against HRS cells cannot be 
carried out. 
 
2.3 Treatment 
 HL represents one of the major success stories of hematology. The disease, 
which was fatal at the beginning, has nowadays 80% of survival rate nowadays. First 
line treatment is typically bleomycin-containing polychemotherapy. ABVD is used 
most likely in Hungary with cycle numbers depending stage and prognosis, which can 
be supplemented by involved field irradiation (IFRT). Patients with early favourable 
disease receive 2-4x ABVD+ 20-30 Gy IFRT. Early Unfavourable disease is usually 
treated 4-6x ABVD+ 30 Gy IFRT. Advanced stage disease is treated with 6-8x ABVD 
± IFRT, where irradiation depends on the presence of initial bulky disease and when 
restaging 18FDG-PET/CT shows residual activity. 
 First line treatment gets 70% of patients into complete remission. About 10-
15% of cases are refractory and 15-20% relapses, most likely in the first 2 years after 
completion of treatment. Half of the patients can be successfully salvaged by 
autologous stem cell transplantation (ASCT). However, treatment of those who relapse 
after ASCT is challenging and has a median survival of 2.5 years. For them anti-CD30 
antibody conjugated with monomethyl auristatin E (MMAE) (brentuximab vedotin), 
PD-1 inhibitors and haploidentic allogenic transplantation can be the chance to survive. 
 
2.4 Brentuximab vedotin 
 Brentuximab vedotin (BV) is the first antibody drug conjugate for 30 years, 
which was approved by American Food and Drug Agency in 2011 (FDA) and European 
Medical Agency (EMA) in 2012 for the treatment of relapsed /refractory (R/R) HL 
patients: following ASCT failure, after two previous lines of therapy in the case of 
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patients unsuitable for ASCT. Recently, BV was approved for patients with high 
relapse risk after ASCT and maintenance therapy. 
 The conjugate itself is polymerase inhibitor; a chimera IgG1 type anti-CD30 
antibody, which is covalently linked to 4 MMAE. The drug links to the surface of 
CD30 positive cells, then it’s internalized and after proteolytic cleavage of MMAE it 
gets to lysosomes. Here, MMAE links to tubulin and causes the apoptosis of CD30 
expressing cell by inhibiting cell cycle from getting G2 to M phase. Cleaved MMAE 
can get through cell membrane to the extracellular space effecting environmental CD30 
negative cells. 
 Phase 1 trial revealed 36% overall response rate (ORR), when drug was 
administered on a 3 weekly basis. By choosing 1.8 mg/kg dose, phase 2 pivotal trial 
revealed 75% ORR when treating 102 heavily pretreated HL patients. Based on this 
result its use was approved. AETHERA was further important trial, when high-risk 
patients (primary refractory or remission duration less than 12 months or extranodal 
involvement at time of salvage treatment pre transplant) received maintenance 
treatment post ASCT on a 3 weekly basis 1.8 mg/kg BV or placebo. BV treated patients 
reached significantly superior PFS, than those receiving placebo (63% vs. 51%). 
 Unacceptable high pulmonary toxicity (44%) was revealed when BV was 
combined with first line ABVD treatment, which was not found, when combined with 
AVD. Failure free survival was found to be 96% through 3 years of follow up in 
examined advanced stage patients (II/A bulky or II/B-IV. stage). Based on these 
promising results, ECHELON-1 trial is currently investigating advanced stage patients 
worldwide comparing BV+AVD vs. standard of care ABVD. (ClinicalTrials.gov 
#NCT01712490) 
 The role of BV is currently investigated in several therapeutic settings and 
combinations, these results are currently evaluated: untreated early unfavourable 
patients, elderly patients, bendamustin, ICE, rituximab, gemcitabin, dacarbazin. 
 
2.5 Pulmonary complications 
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  Currently and recently used bleomycin containing polychemotherapy and 
IFRT involving the chest may cause potential pulmonary toxicity. Bleomycin is mainly 
excreted by the kidneys, but it can be also eliminated by its specific deactivating 
enzyme bleomycin hydrolase (BLMH). Against its chemotherapeutic effectiveness, its 
excessive use is limited by its potentially life-threatening pulmonary toxicity.  It’s toxic 
effect is due to its free radical producing capacity, while its pulmonary specificity is due 
to the fact, that it’ s absent in the lung. 
 Due to the literature pulmonary toxicity occurs in about 20-46% of patients 
treated with bleomycin, while mortality rate is 1-3%. The radiological sign of 
interstitial fibrosis caused by bleomycin is typically bilateral reticular density and pure 
nodular infiltrates. During bleomycin induced pulmonary toxicity free radical 
formation, then DNA damage, pneumocyte and endothelial damage, abnormal cytokin 
cascade formation, inflammation, fibroblast activation, fibrousus extraction, fibrin 
formation and finally interstitial pulmonary fibrosis can be observed. Factors 
predisposing for pulmonary toxicity are age, cumulative dose, smoking, abnormal 
kidney function, route of administration (intravenous or intramuscular). The role of 
granulocyte colony stimulating factor and chest irradiation are debated. In case of acute 
complication omission of bleomycin and parenteral steroid treatment is recommended. 
Favourable effect of imatinib was reported in one case. 
 Pulmonary toxicity of irradiation involving the chest is known, it used to be 
the most frequent cause of pulmonary impairment. Irradiation pneumonitis typically 
occurs 1-3 months after completion of irradiation. The probability of its development 
depends on size of the irradiated area, type of irradiation, daily and total dose of 
irradiation. Definitive fibrosis may occur after 6 months of irradiation. The probability 
of its development depends more on total dose and irradiated size, while daily dose is 
less important in this matter. 
 BLMH, the enzyme inactivating bleomycin may be a possible factor that can 
affect long-term pulmonary function of patients receiving bleomycin. SNP A1450G 
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which inactivates bleomycin, eventually pulmonary toxicity. It looks like SNP A1450G 
is responsible for exchanging isoleucin to valin at the amino acid residuum 443. 
Although exact effect of SNP A1450G to BLMH is unknown, it looks like it could 
affect bleomycin induced DNA damage. The role of BLMH affecting pulmonary 
function of HL patients is unknown in the literature. 
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3. Aims 
 
1. To investigate clinicopathological features of our currently followed HL 
patients (age, gender, histology, stage, general symptoms), to collect treatment 
modalities (chemotherapeutic protocols, type of irradiation and involved 
region) and to evaluate their pulmonary function by using questionnaire, chest 
X-ray, spirometry and lung scintigraphy 
2. To investigate the role of irradiation involving the chest to develop pulmonary 
toxicity after the treatment of HL patients through retrospective evaluation. 
3. To investigate the role of cumulative bleomycin dose to the pulmonary 
function HL patients after treatment through retrospective evaluation. 
4. To investigate the factors reported in the literature that may potentially affect 
lung function of HL patients after treatment through retrospective evaluation. 
5. To evaluate the role of the BLMH SNP A1450G polymorphism among 
previously bleomycin treated HL patients through retrospective pulmonary 
function evaluation. 
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4. Patients and methods 
Evaluation of pulmonary complications of previously treated HL patients’ was 
done at the Department of Hematology, University of Debrecen (UD), between 
November 2012 and October 2013. Patients were informed about the study and test 
methods and Local Research Ethics Committee of University of Debrecen gave 
approval of the study. The following data were collected: gender, age at time of 
diagnosis, clinical stage based on Cotswold modified Ann Arbor staging system, 
histological subtypes according to WHO 2008 classification, presence or absence of 
"B" symptoms, treatment modality (radiotherapy, chemotherapy, combined chemo-
radiotherapy), chemotherapy regimen (ABVD, COPP/ABV, CVPP, other) and 
radiotherapy (involved-field irradiation of the mediastinum or other region, mantle, 
inverted Y, etc.) and elapsed time from treatment. Pulmonary status was assessed by St. 
George Respiratory Questionnaire (SGRQ), spirometry, chest X-ray and dynamic 
inhalation lung scintigraphy.  
SGRQ is a questionnaire validated for pulmonary diseases and it includes 3 
parts: symptom, activity and impact scores, which make the total score, ranging 
between 0 and 100. The higher the value, the worse quality of life the patient reports. 
SGRQ was considered aberrant, when its value was above 10.  
To investigate possible functional deviations, spirometry was done at 
Department of Pulmonology, UD, by EuTest Plus VT-17 spirometer. The main static 
parameters (FRC (functional residual capacity), RV (residual volume), TLC (total 
capacity), FVC (forced vital capacity) and dynamic parameters were investigated 
(FEV1 (forced exspiratory volume in 1 second, Tiffenau (FEV1/FVC), and other 
parameters, like PEF (peak exspiratory flow) and VC (vital capacity). Given financial 
and practical considerations spirometry was performed instead of gold standard DLCO. 
Spirometry results were calculated as percentage of age and gender adjusted healthy 
controls: value above 80% was considered as mild, 50-79% moderate, 30-49% severe 
and below 30% was considered as very severe alterations.  
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Chest X-rays were reviewed, looking for structural alterations, which may 
influence lung function. Chest X-rays with fibrotic shadows were considered as 
positive.  
Dynamic inhalation lung scintigraphy was performed to collect data 
referencing membrane lesions at Department of Nuclear Medicine, UD with the use of 
Technetium-99m diethylene triamine penta-acetic acid (DTPA), results were compared 
to normal values of corresponding age and lung side. Results below normal values were 
considered as positive. The lower the result, the severe the membrane lesion was.  
EDTA-anticoagulated peripheral blood samples were collected of previously 
treated HL patients, which were uniquely identified for encryption of patients’ data. 
Genomic DNA was isolated using MagnaPure 96 System (Roche) according to 
manufacturer’s protocol. Concentration of DNA samples was checked using Magna 
Pure 96 DNA and Viral NA small volume kit by Nanodrop UV photometer. SNP 
A1450G (rs1050565) of the BLMH gene was genotyped using TaqMan genotyping 
assays (Lifetechnologies). Measurements and genotype calling were performed on 
QuantStudio 12K flex instrument (Lifetechnologies) at the Biochemistry and Molecular 
Biology Institute, Genomic Medicine and Bioinformatics Service Provider Laboratory, 
UD. Experiments were done in duplicates. 
Statistical analysis was performed using SPPS version 17 and 22 software. 
Analysis was done using the Fischer’ s exact test, Spearman rank correlation test, 
Mann-Whitney and Chi-square test, multivariate analysis as appropriate. Correlations 
were considered significant if p<0.05. 
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5. Results 
5.1 Patient characteristics 
 A total number of 137 patients were evaluated for pulmonary function over a 
one-year period. There were 75 male (54.74%) and 62 female (45.26%).  Male to 
female ratio was 1.21. Median age was 29 years (range: 16-73 years) at time of 
diagnosis. 72 (52.56%) patients had early stage and 64 (47.72%) patients had advanced 
stage disease. 38 patients (27.74%) had a smoking history. 92 patients (67.15%) 
received combined modality treatment, while 42 patients (30.66%) received only 
chemotherapy and 3 patients (2.19%) irradiation alone. More than half of patients were 
treated with only first line ABVD regimen (56.2%), the remaining received COPP/ABV 
(13.87%), CVPP (5.84%) and other regimens (4.92%). Relapsing patients (18.98%) 
were treated according to institutional guidelines, 6 patients (4.37%) underwent ASCT. 
65 patients received involved field irradiation, out of which 46 received to the 
mediastinal and 19 to the non-mediastinal region. Mantle field irradiation was used for 
20 patients; other irradiation techniques included inverted Y and locoregional 
irradiation (10 patients). Median elapsed time since diagnosis was 11 years (2-30) at the 
time of our work. 
 
5.2 Pulmonary function test results 
 Abnormal pulmonary function was found as the following, according to the 
different test methods: 49 patients (35.77%) had SGRQ score above 10 and 88 
(64.23%) patients below 10 points. 75 patients (54.74%) had negative, 36 patients 
(26.28%) mild, 19 patients (13.87%) moderate, 3 patients (2.19%) severe and 4 patients 
(2.92%) had very severe spirometry alterations. 16 patients (11.68%) had restrictive and 
61 patients (44.52%) had obstructive alterations. 14 patients (10.22%) had central and 
47 patients (34.30%) had peripheral obstruction. Some patients had both restrictive and 
obstructive alterations. 108 patients (78.84%) had no alterations on chest X-ray, while 
29 patients (21.16%) had fibrotic shadows. Lung scintigraphy revealed membrane 
lesions in 48 patients (35.04%), while 89 patients (64.96%) had no alterations.  
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5.3 Evaluation the role of chemotherapeutic cycles and chest irradiation to pulmonary 
function  
 Patients were then subdivided into two groups. Group 1 included those 
receiving combined modality treatment and irradiation therapy alone (n=69 patients), 
when irradiation means exclusively chest irradiation (involved field irradiation to the 
mediastinum + mantle field). Group 2 included patients receiving combined modality 
treatment (with no chest irradiation) and chemotherapy alone (n=68 patients). Any kind 
of chemotherapeutic regimen was allowed in this comparison. No significant additive 
worsening effect of chest irradiation was confirmed with test methods. (SGRQ: p=0.73, 
spirometry: p=0.39, chest X-ray: p=0.69, scintigraphy: p=0.34) 
 When group 1 was narrowed to patients receiving only ABVD and chest 
irradiation (n=37 patients), a significant correlation could be detected between SGRQ 
total score and number of ABVD cycles and subsequent bleomycin dose (p=0.01). The 
more cycles the patient received, the higher score was reached at the SGRQ test. 
 When group 2 was narrowed to patients receiving only ABVD without chest 
irradiation (n=40 patients), a close correlation was found between scintigraphy results 
and number of ABVD cycles and subsequent cumulative bleomycin dose (left side: 
p=0.099, right side: p=0.051). The more cycles the patient received, the worse result 
was detected by scintigraphy. 
 Multivariate analysis was performed in patients receiving first line ABVD 
chemotherapy regarding potential risk factors of late lung impairment (n=77 patients). 
Smoking was a risk factor of SGRQ, spirometry and scintigraphy results. Age affected 
spirometry results. Bleomycin dose also significantly affected SGRQ and scintigraphy 
results. No correlation was found between chest irradiation and any of the test methods. 
All investigated patients had normal pretreatment kidney values; hence it didn’ t 
influence lung impairment in these cases.  
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5.4 Evaluating the role of bleomycin hydrolase gene polymorphism in Hodgkin 
lymphoma patients  
 To further complement our investigations a total number of 131 peripheral 
blood samples were collected from previously treated HL patients. Bleomycin was 
included in the treatment of 102 patients (ABVD, BEACOPP, COPP/ABV, relapsed/ 
refractory patients). The treatment of the remaining 29 patients excluded bleomycin 
(irradiation only, COPP, CVPP), thus representing a control group. Out of the 102 
bleomycin-treated patients 68 received ABVD chemotherapy alone. Median bleomycin 
dose and time elapsed from treatment completion differed significantly in the treatment 
groups. Other factors (smoking, age, bleomycin dose, chest irradiation, kidney function, 
use of colony stimulating factors) that could potentially affect lung function were 
equally represented in all investigated subgroups with no significant differences. 
 
5.5 Distribution of bleomycin hydrolase gene polymorphism 
 BLMH A1450G genotype distribution was determined from blood samples 
collected from patients. Homozygous wild A/A genotype was found in 72 patients 
(55.0%), while 44 patients (33.6%) had heterozygous A/G and 15 patients (11.5%) had 
homozygous mutated G/G genotype, where “A” is the wild (allele frequency: 71.8%) 
and “G” is the mutated allele (allele frequency: 28.2%). Our results were comparable to 
the NCBI SNP database for BLMH SNP A1450G. Allele frequencies were in Hardy-
Weinberg equilibrium. G/G genotype group alone would have been too small for 
relevant statistical analysis, therefore patients were then subdivided into subgroups: one 
containing the mutated allele: A/G+G/G (45.1%) and the other homogenous for the 
wild allele: A/A (55.0%), thus demonstrating the possible role of the wild “A” and 
mutated “G” allele.  
 Factors, which could potentially affect lung function, were equally represented 
between the subgroups containing the mutated allele (A/G+G/G) and those 
homogenous for the wild allele (A/A) even within the investigated treatment groups 
with no significant differences.  
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5.6 Investigation the role of bleomycin hydrolase gene polymorphism to pulmonary 
function   
 All bleomycin- treated patients (n=102) had more favorable lung function test 
results in the A/A genotype group, with every investigated test method with significant 
differences in the forced vital capacity results (FVC), p=0.006. 
 When focusing on patients who received ABVD regimen (n=68) alone, 
significantly more favorable results were seen in the A/A genotype group, with every 
investigated test methods. The SGRQ score was significantly more favorable in the A/A 
genotype group (11.90 pts. vs. 4.20 pts., p=0.035). Right-sided lung scintigraphy results 
were also significantly more favorable in the A/A genotype group (74.81 vs. 57.56, 
p=0.045). Among spirometry results FVC (p=0.020) and forced expiratory volume in 1 
s (FEV1) results were significantly more favorable (p=0.028) in the A/A genotype 
group. A linear regression analysis also confirmed these results. 
 As a control group (n=29), patients treated with agents excluding bleomycin 
(irradiation or chemotherapeutic regimens not containing bleomycin) were tested with 
no significant differences between A/G+G/G and A/A genotype groups. 
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6. Discussion 
 Currently used first-line treatment of HL, bleomycin containing ABVD and/or 
radiotherapy involving the chest is reported to produce pulmonary side effects such as 
bleomycin-induced lung injury (BILI) and radiation-induced pneumonitis.  
 In our study, abnormal pulmonary function was detected in between 21-45% 
of patients and found to be correlated with smoking, age and cumulative bleomycin 
dose.   
 Bleomycin is usually administered 10 mg/m2 intravenously or intramuscularly.  
While the half-life of bleomycin is comparable with iv. and im. administration, peak 
plasma level of im. administration is only one tenth of iv. administration. In the current 
study bleomycin was administered exclusively intramuscularly and dose was 
maximized in 15 mg, hence providing basis, that only one acute pneumonitis occurred, 
which was considered bleomycin toxicity. Our workgroup also published our patient’ s 
survival data, which is comparable to international survival rates. The reason may be, 
that more clear associations can be found in patients receiving ABVD, that they were 
treated later (1999-present), hence there are less confounding factors that could 
contribute to pulmonary functions. 
 Combination of brentuximab vedotin with first-line ABVD revealed an 
additive lung damage effects of bleomycin, hence administering brentuximab vedotin is 
recommended only with AVD (adriamycin, vincristine, dacarbazine) chemotherapy. 
The German Hodgkin Study Group is currently investigating the role of brentuximab 
vedotin by developing BEACOPPescalated (bleomycin, etoposide, doxorubicin, 
cyclophosphamide, vincristine, procarbazine, and prednisone) to two experimental 
variants BrECAPP (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, 
procarbazine, prednisone) and BrECADD (brentuximab vedotin, etoposide, 
cyclophosphamide, doxorubicin, dacarbazine, dexamethasone). The product description 
of brentuximab vedotin also reports pulmonary toxicity as single agent, like 
pneumonitis, intersititial lung disease, acute respiration distress syndrome (ARDS). 
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Nevertheless, in these cases an obvious relationship was not established, but the risk of 
pulmonary toxicity could not have been excluded.  
 Nowadays, due to the combined modality treatments, only stage I/A nodular 
lymphocyte predominant HL patients are treated with radiotherapy alone, furthermore 
irradiated area is also notably smaller (involved-field or involved-node irradiation). 
According to the literature, chest irradiation does not significantly contribute to the 
pulmonary damage of bleomycin, however it prolongs the duration of reversible 
damage. Nevertheless, the additive negative effect of thoracic irradiation is debated. 
Our results confirm this statement; currently used chest irradiation did not significantly 
worsen pulmonary function.  
 A biomarker would be mandatory, which would be of help even in 
combination with other pulmonary risk factors. In the presence of such biomarker 
patients could be chosen to eliminate bleomycin from their treatment and could be 
replaced with targeted therapeutic agents.  
 BLMH gene SNP A1450G has been investigated previously in testicular germ-
cell cancer (TC) patients in correlation with survival data. Mutant variant (G/G) 
genotype was associated with decreased survival compared to the heterozygous (A/G) 
and the wild type variants (A/A). SNP A1450G was also investigated in correlation 
with pulmonary toxicity of TC patients in a subsequent study. Interestingly, no 
association was found of gene polymorphism either with acute bleomycin-induced 
pneumonitis or with pulmonary function tests performed during treatment.  
 In the current study BLMH gene SNP A1450G polymorphism led to 
significant differences in the follow-up pulmonary test results of ABVD-treated HL 
patients. The authors believe, that the observed difference in the ABVD only group is 
due to the genotype differences, and not due to other factors, that could possibly affect 
pulmonary function, since these factors were equally represented between the treatment 
groups and also in the control group. 
 Dutch authors explained the lack of correlation with barely injured kidney 
function, when the effect of altered BLMH activity is negated by the rapid elimination 
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of bleomycin. Because the serum half-life of bleomycin is relatively short, the effect of 
altered BLMH activity could have been negated by the rapid elimination of bleomycin. 
The fact, that homozygous variant (G/G) TC patients in the Dutch-study were 
associated with decreased survival could be explained by the fact that in this genotype 
group, there were more patients with refractory disease, than in other groups. This 
suggests, that it may not have been an independent parameter in terms of survival. 
Authors describe, that G/G genotype variant could have been associated with other 
factors that causes tumor resistance. The fact that they didn’t find association of SNP 
A1450G and acute pulmonary toxicity can be explained also, that they investigated the 
occurrence of acute pulmonary toxicity, whereas, our study investigated quantitative 
features of long-term pulmonary toxicity. Compared to the TC patients of the Dutch 
study, our patients were treated with lower cumulative bleomycin doses administered 
im., and still had normal kidney function results. All of these factors represent major 
differences. Previously, the difference between im. and iv. administration was described 
and the maximized 15 mg dose of bleomycin. Given a median 120 mg/m2 bleomycin 
dose, a maximum of 180 mg bleomycin could have been administered, which is far less, 
than what the TC patients received (3-400 mg). Overall, BLMH gene SNP A1450G 
polymorphism seems to have significance on the long-term. Obviously, the different 
nature of the diseases may also have contributed to these conflicting results. 
 Limitation of the control group is, that control patients cannot be matched in 
elapsed time since treatment with the investigated (ABVD) patient population. We were 
looking for a patient group, whose treatment did not included bleomycin to show, that 
BLMH had no role to pulmonary function in these patients. However such treatment 
modalities existed only in the reported 15-44 years of follow up period. We did not find 
any other historical, patient group with hematological disease, who could have been 
matched in either age or general condition to our investigated HL patient population. 
We are planning to compare the BLMH polymorphism data of brentuximab vedotin-
AVD and standard of care ABVD arms of currently running clinical trials. Evaluation 
of these results is currently in progress.  
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 As a summary of our work, it can be concluded, that chest irradiation – as part 
of current treatment of HL patients – doesn’t significantly worsen pulmonary side 
effects. In terms of pulmonary side effects avoiding chest irradiation is not 
recommended – if other pulmonary risk factors are not present. However, increasing 
cumulative bleomycin dose may cause further side effects. Our results further confirm 
current endeavor, which try to reduce chemotherapeutic cycles, while maintaining 
favourable survival rates. Because the investigated BLMH polymorphism led to 
significant differences in long-term pulmonary side effects of patients, further study is 
planned to confirm our results. 
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7. Novel statements 
 
1. Currently used involved field irradiation for the treatment of HL patients 
doesn’t contribute to the pulmonary toxicity in case of irradiation involving the 
chest after treating HL patients, through retrospective analysis. The decrease 
or abandonment of irradiation is irrelevant – based on these results. 
2. Increasing chemotherapeutic cycles and hence cumulative bleomycin dose 
pulmonary function worsened after treating HL patients, through retrospective 
analysis. Bases on these results, reducing bleomycin-containing chemotherapy 
is recommended, while maintaining curative efficacy.  
3. Multivariate analysis confirmed that smoking and age are potentially 
pulmonary toxic factors after treating HL patients, through retrospective 
analysis. 
4. BLMH gene SNP A1450G polymorphism led to significant differences in the 
long-term follow-up pulmonary test results of ABVD-treated HL patients. 
Based on our results, investigating the further role of BLMH gene SNP 
A1450G polymorphism is recommended. 
5. Clinical significance of our work would be, that based on BLMH gene SNP 
A1450G polymorphism exact cases could be chosen even with multiple 
pulmonary risk factors, whose treatment did not include bleomycin but would 
be replaced by targeted therapeutic options. 
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